Dave Ricks, CEO of Eli Lilly | The All-In Interview

(2:06) The obesity problem: a global chronic health epidemic (13:07) The history of discovering GLP-1s (20:38) Impact of GLP-1s on different human functions (27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs (33:11) Responding to criticism and research of GLP-1 dependency (40:04) Stock performance, dealing with political pressure related to successful drugs (47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about (56:09) Scaling and impacting culture at a 100+ year-old company